Page 2 - Nppa

Price hike, at last

Govt should not control drug prices

Ceiling prices of 21 key medicines raised by 50%; NPPA invokes DPCO 2013

The prices of APIs have gone up in the range of 5-88%

Health care sector is on a recovery path after muted performance: Icra

The strong performance of the sector is in line with our expectations: Icra

Will not allow cost of knee implants to rise beyond 10% in a year: Govt

The NPPA notified the ceiling price of orthopaedic knee implants on 16th August, 2017

Drug pricing regulator recovers just 14% dues from pharma firms in 21 years

The NPPA website notes that the amount still under litigation is around Rs 4,084.05 crore

NPPA undermined

Govt decides to have bureaucracy set drug prices

By March 15, medical devices firms must submit price data: NPPA ultimatum

This is in order to monitor the price movement of 19 medical devices out of 23 medical devices notified as drugs under the Drugs and Cosmetics Acts

NPPA fixes retail prices of 14 formulations

The formulations with fixed retail prices include Telmisartan and Chlorthalidone Tablet used in treating high blood pressure marketed by Sun Pharma

NPPA caps prices of 39 drugs used for treating cancer, malaria

The steps are in continuation of the government's drive to make affordable quality medicines available to patients

Set up tribunal to hear firms' drug price appeals: NPPA

Setting up of an advisory committee has been a long-standing demand of the industry

NPPA fines health hub for overcharging on stents

On February 13, NPPA had capped the price of drug-eluting stents at Rs 29,600

NPPA fixes ceiling price of 30 more formulations

Total number of formulations under the price control since April 2016 has reached around 760

NPPA finalises format to monitor price of 19 medical devices

Currently, the government monitors the price movement of 19 medical devices

NPPA revises rates of 6 drugs, fixes price of 1 medicine

It has fixed the price of P-PPi-L capsules which are used for treating acidity

No proposal to extend price cap to other medical devices, says NPPA chief

National Pharmaceutical Pricing Authority (NPPA) chairman Bhupendra Singh has said there was no proposal "as of now" to extend a price cap to other medical devices.The government has categorised 22 medical devices as drugs. Among these, four products, including cardiac stents, are categorised as scheduled drugs and NPPA can cap their price under law. In respect of other devices such as catheters, heart valves and intra ocular devices (categorised as non-scheduled drugs), the government allows for a 10 per cent price hike in a year.While the NPPA is monitoring the prices, fixing those for other devices is not on the agenda, Singh said on Thursday. He met representatives of pharmaceutical companies and hospitals in this city, to understand their concerns on drug pricing and particularly on capping of stent prices. Singh said all the stents being sold in India will continue to be available. On Wednesday, NPPA rejected requests from device makers Abbott Healthcare and Medtronic ..

NPPA fixes prices of 20 drugs, stents made costlier

Drug Eluting Stents will now be priced at Rs 30,180 and Bare Metal Stents at Rs 7,400

Medical devices notified as drug should carry MRP on packs: NPPA

The government has notified 22 medical devices as drugs under the Drugs and Cosmetics Act, 1940

NPPA's drug overcharging penalty at a record high

The regulator has registered 1,493 cases of overcharging since its inception in 1997

A few more drugs to come under price control: NPPA

The regulator has been fixing and revising the prices of drugs

NPPA heat on hospitals for failing to provide stent details

Hospitals not providing these details could be accused of distorting evidence deliberately